Abstract
Because of adverse reactions, early efforts to introduce high affinity competitive or use-dependent NMDA receptor antagonists into patients suffering from stroke, head trauma or epilepsy met with failure. Later it was discovered that both low affinity use-dependent NMDA receptor antagonists and compounds with selective affinity for the NR2B receptor subunit met the criteria for safe administration into patients. Furthermore, these low affinity antagonists exhibit significant mechanistic differences from their higher affinity counterparts. Success of the latter is attested to the ability of the following low affinity compounds to be marketed: 1) Cough suppressant - dextromethorphan (available for decades) 2) Parkinsons disease - amantadine, memantine and budipine 3) Dementia - memantine and 4) Epilepsy - felbamate. Moreover, Phase III clinical trials are ongoing with remacemide for epilepsy and Huntingtons disease and head trauma for HU-211. A host of compounds are or were under evaluation for the pos sible treatment of stroke, head trauma, hyperalgesia and various neurodegenerative disorders. Despite the fact that other drugs with associated NMDA receptor mechanisms have reached clinical status, this review focuses only on those competitive and use-dependent NMDA receptor antagonists that reached clinical trails. The ensuing discussions link the in vivo pharmacological investigations that led to the success / mistakes / failures for eventual testing of promising compounds in the clinic.
Keywords: NMDA Receptor, Neuropathologies, NR1 / NR2A receptor, transient neuronal vacuoles, CPPene, Dextromethorphan, Felbamate, Selfotel, MK801, STROKE PRECLINICAL, TRAUMATIC BRAIN INJURY (TBI)
Current Drug Targets
Title: Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Volume: 2 Issue: 3
Author(s): Gene C. Palmer
Affiliation:
Keywords: NMDA Receptor, Neuropathologies, NR1 / NR2A receptor, transient neuronal vacuoles, CPPene, Dextromethorphan, Felbamate, Selfotel, MK801, STROKE PRECLINICAL, TRAUMATIC BRAIN INJURY (TBI)
Abstract: Because of adverse reactions, early efforts to introduce high affinity competitive or use-dependent NMDA receptor antagonists into patients suffering from stroke, head trauma or epilepsy met with failure. Later it was discovered that both low affinity use-dependent NMDA receptor antagonists and compounds with selective affinity for the NR2B receptor subunit met the criteria for safe administration into patients. Furthermore, these low affinity antagonists exhibit significant mechanistic differences from their higher affinity counterparts. Success of the latter is attested to the ability of the following low affinity compounds to be marketed: 1) Cough suppressant - dextromethorphan (available for decades) 2) Parkinsons disease - amantadine, memantine and budipine 3) Dementia - memantine and 4) Epilepsy - felbamate. Moreover, Phase III clinical trials are ongoing with remacemide for epilepsy and Huntingtons disease and head trauma for HU-211. A host of compounds are or were under evaluation for the pos sible treatment of stroke, head trauma, hyperalgesia and various neurodegenerative disorders. Despite the fact that other drugs with associated NMDA receptor mechanisms have reached clinical status, this review focuses only on those competitive and use-dependent NMDA receptor antagonists that reached clinical trails. The ensuing discussions link the in vivo pharmacological investigations that led to the success / mistakes / failures for eventual testing of promising compounds in the clinic.
Export Options
About this article
Cite this article as:
Palmer C. Gene, Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies, Current Drug Targets 2001; 2 (3) . https://dx.doi.org/10.2174/1389450013348335
DOI https://dx.doi.org/10.2174/1389450013348335 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epilepsy and Neurosurgery: Historical Highlights
Current Pharmaceutical Design Electroconvulsive Therapy in Child and Adolescent Psychiatry
Current Psychiatry Reviews Physiological and Pharmacological Insights into the Role of Ionic Channels in Cardiac Pacemaker Activity
Cardiovascular & Hematological Disorders-Drug Targets Co-Existence of GABA and Glu in the Hippocampal Granule Cells: Implications for Epilepsy
Current Topics in Medicinal Chemistry Graphical Abstracts:
Letters in Drug Design & Discovery Intrahippocampal Amyloid-β (1-40) Injections Injure Medial Septal Neurons in Rats
Current Alzheimer Research Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders
Mini-Reviews in Medicinal Chemistry Comparison of HPLC-DAD and UPLC-MS/MS in Monitoring Serum Concentration of Lamotrigine
Current Pharmaceutical Analysis Endoplasmic Reticulum Protein Quality Control in Neurodegenerative Disease: The Good, the Bad and the Therapy
Current Medicinal Chemistry Anesthetics as Chemical Tools to Study the Structure and Function of Nicotinic Acetylcholine Receptors
Current Protein & Peptide Science Ethnic and Geographical Differences in Ischaemic Stroke Among Young Adults
Current Vascular Pharmacology PLGA Nanoparticles for Nose to Brain Delivery of Clonazepam: Formulation, Optimization by 32 Factorial Design, In Vitro and In Vivo Evaluation
Current Drug Delivery Microendophenotypes of Psychiatric Disorders: Phenotypes of Psychiatric Disorders at the Level of Molecular Dynamics, Synapses, Neurons, and Neural Circuits
Current Molecular Medicine Recent Advances in Antiepileptic Herbal Medicine
Current Neuropharmacology Glycaemic Control: A Balancing Act or A Different Approach?
Current Diabetes Reviews Targeting the Role of Astrocytes in the Progression of Alzheimers Disease
Current Signal Transduction Therapy Amyloid β Oligomers Decrease Hippocampal Spontaneous Network Activity in an Age-Dependent Manner
Current Alzheimer Research Analysis of Functional Brain Images Using Population-Based Probabilistic Atlas
Current Medical Imaging Pharmacology of Recombinant Low-Voltage Activated Calcium Channels
Current Drug Targets - CNS & Neurological Disorders Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation